Mounjaro vs Wegovy vs Ozempic UK — Complete Comparison Guide (2026)

Mounjaro, Wegovy, and Ozempic are the three GLP-1 medications driving the UK weight loss injection conversation. They are not interchangeable. They contain different active ingredients (or different doses of the same ingredient), work through different mechanisms, produce different weight loss results, carry different NHS statuses, and cost very different amounts — especially after Mounjaro’s significant price increase in late 2025.

This guide covers everything you need to make an informed decision or understand where you are in your treatment. It is built on the full clinical trial data, current UK prescribing reality, and honest cost comparisons as of 2026 — not pharmaceutical marketing copy.

The three medications at a glance

How each one works — and why the difference matters

GLP-1 receptor agonism — the shared mechanism

All three medications activate GLP-1 (glucagon-like peptide-1) receptors. GLP-1 is a hormone naturally produced by the gut after eating — it signals to the brain that food has been consumed, stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. Activating GLP-1 receptors pharmacologically produces all these effects continuously, not just after meals.

The GIP difference — why Mounjaro works differently

Mounjaro goes further. Tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors — making it a dual agonist. GIP receptors are found not only in the pancreas but also in adipocytes (fat cells). The GIP receptor component of tirzepatide appears to:

• Enhance insulin secretion synergistically with GLP-1 activation
• Directly affect adipose tissue metabolism — promoting fat oxidation and reducing fat accumulation
• Reduce the GI side effects that GLP-1 activation alone produces — potentially explaining why Mounjaro has lower diarrhoea rates than Wegovy despite being more effective

Weight loss results compared — the clinical evidence

Head-to-head data

The SURMOUNT-MMO trial (2024) was the first adequately powered head-to-head comparison of tirzepatide vs semaglutide 2.4mg. It confirmed what separate trials suggested: tirzepatide produces significantly greater weight loss than semaglutide at comparable timepoints. This was not a surprise to researchers — the dual mechanism produces a stronger combined effect — but it settled the question definitively.

What the weight loss numbers mean at real UK body weights

These are population averages. Individual results vary substantially. Roughly one-third of people on any of these medications lose significantly more than the average; one-third lose significantly less. Protein intake, exercise, sleep quality, and dose reached all influence where you land.

Cardiovascular outcomes — a critical difference

This matters: if you have established cardiovascular disease — previous heart attack, stroke, heart failure — Wegovy has the proven cardiovascular outcome data that Mounjaro does not yet have. For many cardiologists and GPs, this is the deciding factor regardless of weight loss efficacy.

Side effects compared — what the data actually shows

The GI side effect pattern difference — clinically important

Wegovy and Mounjaro have very different GI side effect profiles despite similar overall nausea rates:

• Mounjaro is more likely to cause constipation (12–17%) — the GIP component appears to partially counteract GLP-1’s gut motility effects, resulting in slower transit rather than faster
• Wegovy is more likely to cause diarrhoea (29%) and vomiting (24%) — the pure GLP-1 mechanism with no GIP counterbalance produces stronger gut motility changes

People who cannot tolerate Wegovy’s diarrhoea often switch to Mounjaro and find the GI profile significantly easier. Conversely, people who struggle with Mounjaro’s constipation sometimes find Wegovy easier to manage. Individual response is the ultimate determinant.

UK cost comparison 2026 — the full picture

The cost-efficacy analysis — which gives best value per kg lost?

These are rough estimates based on average trial outcomes and typical mid-range UK pricing. Individual results and provider costs vary. The key takeaway: after the Mounjaro price increase, Wegovy 2.4mg offers better cost-per-kg-lost value for most patients, and Wegovy 7.2mg approaches Mounjaro efficacy at lower cost.

NHS access UK — who can get what

The practical NHS reality

For most UK adults seeking GLP-1 medication for weight loss in 2026:

• The NHS route most likely to succeed is asking your GP about the Wegovy NICE pathway — the criteria are achievable and the pathway exists
• If you meet Wegovy NHS criteria, the prescription charge (~£9.90) vs private cost (£130–£295/month) makes it dramatically more cost-effective
• Mounjaro NHS access for weight management remains very limited in practice — most access is private
• NHS Ozempic for weight loss is not available — do not expect a GP to prescribe it for this purpose

Missed dose rules — all three side by side

If you are switching between medications — the missed dose logic changes. Always clarify with your prescriber what rule applies during any transition period.

Who should choose which — the decision framework

Mounjaro — full verdict

Full dose guide: Mounjaro Dose Guide UK — 2.5mg to 15mg

Wegovy — full verdict

Full dose guide: Wegovy Dose Guide UK — 0.25mg to 7.2mg

Ozempic — full verdict

Full dose guide: Ozempic Dose Guide UK — 0.25mg to 2mg

Switching between medications — what you need to know

Why all switches to a different molecule start at the lowest dose

Even if you have been on Wegovy 2.4mg for 12 months and your GI tract is well adapted to semaglutide, switching to tirzepatide (Mounjaro) requires starting from 2.5mg. The GIP receptor component of tirzepatide is entirely new to your system — it requires the same adaptation period as any first-time GLP-1 user. Attempting to start Mounjaro at a higher dose after stopping Wegovy would produce severe GI side effects.

Supplements — what you need regardless of which medication

The nutritional gaps created by reduced food intake on GLP-1 medication are the same regardless of which medication you are on. The only differences are in the GI symptom focus:

Nutrition principles that apply to all three medications

Regardless of which medication you are on, the nutritional principles are identical. The food choices that make the difference are the same whether you are on Mounjaro, Wegovy, or Ozempic:

What happens when you stop — all three medications

Weight regain after stopping GLP-1 medication is consistent across all three medications. The biology is the same — removing the pharmacological appetite suppression allows the underlying hormonal drivers of obesity (elevated ghrelin, reduced leptin, altered food reward pathways) to reassert themselves.

The consistent message from all trial data: weight management is a long-term condition. These medications address the biological mechanisms of obesity — removing them allows those mechanisms to return. Long-term use with lifestyle support produces the best sustained outcomes.

If you need to stop — minimising regain on all three

• Discuss structured tapering with your prescriber — gradual dose reduction moderates the appetite rebound vs abrupt stopping
• Increase protein intake significantly — protein is the primary non-medication hunger management tool
• Maintain and if possible increase exercise — physical activity partially replaces the appetite-suppressing effect
• Continue supplement stack — Daily Fuel, Triple Magnesium, Electrolytes, and Vitamin D3+K2 remain relevant after stopping
• Consider switching rather than stopping — if stopping due to side effects or cost, switching medications may be better than stopping entirely

Complete FAQ — 40+ questions answered

Week-by-week experience — what each medication actually feels like

Clinical trial data tells you what happens on average across thousands of people. What it does not tell you is what starting one of these medications actually feels like week by week — what changes, when it gets hard, and when you know it is working. Here is an honest account based on what the research and real-world experience shows for each medication.

Mounjaro — the week-by-week experience

Wegovy — the week-by-week experience

Ozempic — the week-by-week experience

Real-world results vs clinical trial results — what to expect in practice

Clinical trial results are often described as “average weight loss” figures. In reality, the distribution of outcomes is wide — and understanding that distribution matters more for setting personal expectations than the average alone.

The distribution of outcomes — not everyone gets the average

The practical implication: roughly 1 in 10 people on Mounjaro and 1 in 6 on Wegovy will be non-responders or minimal responders (<5% weight loss) despite full adherence to the medication and treatment protocol. This is not a failure of willpower — it reflects genuine biological variability in GLP-1 and GIP receptor sensitivity. If you are not responding after 3–4 months at therapeutic doses with all lifestyle factors addressed, discuss switching medications with your prescriber.

Real-world UK results — what clinical services are seeing

Second Nature, a UK weight management service, published 12-month real-world data on semaglutide-supported programmes showing 19.1% average weight loss at 12 months — meaningfully higher than the STEP-1 trial’s 14.9% at 68 weeks. The difference likely reflects:

• Structured lifestyle support alongside medication (as recommended by NICE)
• Higher protein targets and dietary coaching
• Regular monitoring enabling faster plateau identification and response
• Self-selection of highly motivated participants in private programmes

The lesson: the medication alone produces the trial results. The medication plus good nutritional support and regular monitoring consistently outperforms the trial data.

Type 2 diabetes considerations — how treatment goals change the decision

For people managing Type 2 diabetes, the medication choice calculation is different. Weight loss is often still a goal, but HbA1c reduction, cardiovascular outcomes, and kidney protection may be equally or more important clinical priorities.

The sulfonylurea and insulin interaction — critical for T2DM patients

All three medications significantly improve insulin sensitivity. For T2DM patients on sulfonylureas (gliclazide, glibenclamide, glimepiride) or insulin, starting any GLP-1 medication creates hypoglycaemia risk as two glucose-lowering mechanisms operate simultaneously. Your prescriber should proactively reduce sulfonylurea or insulin doses before starting — not wait for a hypoglycaemia episode. If your prescriber does not mention this, raise it yourself.

Contraception and pregnancy — important for all three

All three medications share similar reproductive considerations that every person of reproductive age should understand before starting.

The oral contraceptive risk is real and underreported. GLP-1 medications slow gastric emptying, which reduces the absorption of oral contraceptives — potentially reducing their effectiveness. The risk is greatest in the 4 weeks after each dose increase when gastric slowing is most pronounced. Discuss with your GP before starting any GLP-1 medication if you are using oral contraception.

Who should not take these medications — contraindications

Injection technique — all three medications

All three are subcutaneous injections using autoinjector pens. The injection sites, technique, and storage principles are similar across all three.

Approved injection sites — all three medications

Injection technique — reducing side effects and reactions

• Always let the pen reach room temperature — remove from the fridge at least 30 minutes before injecting. Cold medication causes more discomfort and may alter absorption.
• Let the alcohol wipe dry completely — injecting through wet skin increases stinging. Wait 30 seconds after wiping before injecting.
• Inject slowly and hold for the full count — the autoinjector will click or indicate completion; hold in place until the full dose has delivered.
• Rotate sites consistently — do not inject the same spot more than once per month. Repeated injection in one area causes lipohypertrophy — hard, fibrous tissue that absorbs medication inconsistently.
• Never inject into scar tissue, bruises, or inflamed skin.

Storage comparison

Health monitoring during treatment — what should be tracked

All three medications require ongoing prescriber oversight. What should be monitored and how frequently:

Diet and exercise — maximising results on each medication

Why diet quality matters more than diet quantity on GLP-1 medications

GLP-1 medications handle the quantity side of the equation — they suppress appetite and reduce calorie intake automatically for most people. What they do not do is ensure that the reduced calorie intake is nutritionally optimal. The people who achieve the best body composition outcomes — losing fat rather than fat and muscle, emerging with definition rather than a deflated appearance — are those who use the appetite suppression window to actively improve dietary quality, not just eat less of the same foods.

The three nutritional differences that matter most on any GLP-1 medication:

Exercise — what actually works on GLP-1 medications

Hitting a plateau — what to do on any GLP-1 medication

Plateaus are universal on GLP-1 medications — they are not a sign of treatment failure. They are a predictable consequence of the body reducing its energy expenditure as it adapts to the deficit. Understanding the causes allows you to address them systematically rather than assuming the medication has stopped working.

The plateau checklist — work through this before escalating dose

Long-term treatment planning — thinking beyond 12 months

GLP-1 medications are not short-term interventions. The clinical evidence — SURMOUNT-4, STEP-4, STEP-5 — is unambiguous: most people regain significant weight after stopping. Planning for this from the beginning produces better outcomes than treating each medication stage as a short-term fix.

The four long-term scenarios and what each means

The habits that determine long-term success — on or off medication

The people who maintain the most weight loss after stopping GLP-1 medication are those who used the treatment period to genuinely establish these habits — not as restrictions imposed by the medication, but as preferences that replaced previous patterns:

1. Default protein-first eating: reaching for Greek yoghurt, cottage cheese, or a protein shake without thinking about it
2. Consistent daily walking: 7,000–10,000 steps per day as a baseline, not a target
3. Reduced alcohol consumption: most people consume significantly less on GLP-1 medication; maintaining this off-medication is one of the highest-leverage changes
4. Scheduled eating rather than grazing: regular meal times rather than continuous snacking
5. Continued supplementation: Daily Fuel, electrolytes, magnesium, and vitamin D3 remain relevant indefinitely

More FAQs — additional questions answered

Master comparison table — everything at a glance

📋 Download the free 14-day meal plan — designed for GLP-1 users on any medication.

Full dose guides: Mounjaro Dose Guide UK | Wegovy Dose Guide UK | Ozempic Dose Guide UK

Related: GLP-1 Side Effects UK | Best Supplements on GLP-1 UK | How to Maximise Results on GLP-1 UK | Hair Loss on GLP-1 UK